Enzo Biochem Inc. said it has received a European Patent Officepatent with claims broadly covering genetic antisensetechnology.
Patents covering the same technology, to which the New Yorkcompany has exclusive rights, have already been allowed bythe U. S. Patent and Trademark Office and are expected to issueshortly.
Enzo (ASE:ENZ) is currently holding discussions with companiesinterested in licensing the gene-regulation technology.
(c) 1997 American Health Consultants. All rights reserved.